sing a intravenous Iron formulation for treating anemia due to iron deficiency
Not Applicable
- Conditions
- Health Condition 1: D500- Iron deficiency anemia secondary to blood loss (chronic)Health Condition 2: D508- Other iron deficiency anemias
- Registration Number
- CTRI/2024/07/071219
- Lead Sponsor
- AIIMS Guwahati
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.All patients = 18 years of age with confirmed diagnosis of Iron deficiency anemia
2.Those who have given consent
Exclusion Criteria
1.Patients with previous history of hypersensitivity reaction to any of the parenteral iron products
2.Pregnant females
3.Patients with concurrent Vitamin B12 deficiency
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cost analysis of Intravenous Ferric Carboxymaltose for treatment of Iron deficiency anemia in a tertiary care centreTimepoint: Data collection at 2 time points: <br/ ><br>1) At the time of diagnosis <br/ ><br>2) Assessment of therapeutic response 1 month after the first dose of Injection Ferric Carboxymaltose
- Secondary Outcome Measures
Name Time Method Safety, efficacy and acceptability of Intravenous Ferric Carboxymaltose for treatment of Iron deficiency anemia in a tertiary care centreTimepoint: Data collection at 2 time points: <br/ ><br>1) At the time of diagnosis <br/ ><br>2) Assessment of therapeutic response 1 month after the first dose of Injection Ferric Carboxymaltose